601 related articles for article (PubMed ID: 22867630)
1. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
[TBL] [Abstract][Full Text] [Related]
2. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
Marfella R; Barbieri M; Grella R; Rizzo MR; Nicoletti GF; Paolisso G
J Diabetes Complications; 2010; 24(2):79-83. PubMed ID: 19261490
[TBL] [Abstract][Full Text] [Related]
3. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
[TBL] [Abstract][Full Text] [Related]
4. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
5. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Rizzo MR; Barbieri M; Marfella R; Paolisso G
Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
7. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
[TBL] [Abstract][Full Text] [Related]
9. Reply to the "Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'", by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353).
Marfella R; Paolisso G
J Diabetes Complications; 2011; 25(6):405-6. PubMed ID: 21775165
[No Abstract] [Full Text] [Related]
10. Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83).
Avogaro A
J Diabetes Complications; 2011; 25(5):352-3. PubMed ID: 21334926
[No Abstract] [Full Text] [Related]
11. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
Göke R; Eschenbach P; Dütting ED
Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
[TBL] [Abstract][Full Text] [Related]
14. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
15. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
16. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
[TBL] [Abstract][Full Text] [Related]
17. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Monnier L; Colette C; Comenducci A; Vallée D; Dejager S
Diabetes Technol Ther; 2012 Oct; 14(10):943-50. PubMed ID: 22775317
[TBL] [Abstract][Full Text] [Related]
18. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
[TBL] [Abstract][Full Text] [Related]
19. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
Chatterjee S; Chatterjee S
Am J Ther; 2015; 22(3):195-8. PubMed ID: 23665884
[TBL] [Abstract][Full Text] [Related]
20. Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Tani S; Takahashi A; Nagao K; Hirayama A
Am J Cardiol; 2015 Feb; 115(4):454-60. PubMed ID: 25637323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
